Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer

Pellini, Bruna; Szymanski, Jeffrey J.; Chin, R; Jones, Paul A.; Chaudhuri, Aadel A.

doi:10.1016/j.thorsurg.2020.01.005

Cited by 22 publications

(23 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can not only be used for prenatal screening [74], analysis of immune diseases [75,76], but also have very important clinical value in oncology. It has been reported in colorectal cancer, breast cancer, non-small cell lung cancer, and other tumors [77][78][79][80][81][82]. e value of cfDNA/ctDNA can be demonstrated and utilized through diagnosis, monitoring of therapeutic response, recurrence and drug resistance, and prognosis.…”

Section: Future Directions and Challengesmentioning

confidence: 99%

Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?

Zhu

Teng

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

In recent years, the studies on ovarian cancer have made great progress, but the morbidity and mortality of patients with ovarian cancer are still very high. Due to the lack of effective early screening and detecting tools, 70% of ovarian cancer patients are diagnosed at an advanced stage. The overall survival rate of ovarian cancer patients treated with surgical combined with chemotherapy has not been significantly improved, and they usually relapse or resist chemotherapy. Therefore, a novel tumor marker is beneficial for the diagnosis and prognosis of patients with ovarian cancer. As the index of “liquid biopsy,” circulating cell-free DNA/circulating tumor DNA (cfDNA/ctDNA) has attracted a lot of attention. It has more remarkable advantages than traditional methods and gives a wide range of clinical applications in kinds of solid tumors. This review attempts to illuminate the important value of cfDNA/ctDNA in ovarian cancer, including diagnosis, monitoring, and prognosis. Meanwhile, we will present future directions and challenges for detection of cfDNA/ctDNA.

show abstract

Section: Future Directions and Challengesmentioning

confidence: 99%

Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?

Zhu

Teng

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Moving to the role of LB in localized disease, the detection and molecular characterisation of minimal residual disease (MRD) is of particular importance. MRD evaluation can improve patient selection for adjuvant therapy, contributing to clinical outcomes while avoiding overtreatments [ 44 ]. Several studies have suggested that ctDNA can be used to detect the presence of MRD after surgical resection in several cancer types, including LC, by documenting a marked decline in presurgical and postsurgical levels of ctDNA [ 143 , 144 ].…”

Section: Future Perspectivesmentioning

confidence: 99%

“…Both approaches have strengths and limitations. PCR-based assays are highly sensitive, able to detect variants with a frequency as low as 0.01%, less expensive and straightforward than NGS, but restricted to the detection of limited pre-planned alterations [ 40 , 44 ]. NGS approaches are more complex but allow the detection of multiple alterations in different genes simultaneously.…”

Section: Introductionmentioning

confidence: 99%

“…They can embrace "whole" alterations or be selected for targeted panels, being this one the most used for clinical application due to the highest sensitivity, lower cost, and simplicity of interpretation. Generally, NGS techniques can be amplicon-based or hybrid-capture-based, accounting for differences in test performance and the range of alterations capable of being detected [ 39 , 44 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management

et al. 2021

View full text Add to dashboard Cite

Liquid biopsy (LB) has boosted a remarkable change in the management of cancer patients by contributing to tumour genomic profiling. Plasma circulating cell-free tumour DNA (ctDNA) is the most widely searched tumour-related element for clinical application. Specifically, for patients with lung cancer, LB has revealed valuable to detect the diversity of targetable genomic alterations and to detect and monitor the emergence of resistance mechanisms. Furthermore, its non-invasive nature helps to overcome the difficulty in obtaining tissue samples, offering a comprehensive view about tumour diversity. However, the use of the LB to support diagnostic and therapeutic decisions still needs further clarification. In this sense, this review aims to provide a critical view of the clinical importance of plasma ctDNA analysis, the most widely applied LB, and its limitations while anticipating concepts that will intersect the present and future of LB in non-small cell lung cancer patients. Graphical Abstract

show abstract

“…CfDNA fragments are 150 to 200 bp long; have a short half-life (about two and a half hours), which makes them suitable for analysis of tumour mutations, monitoring of treatment response, and minimal residual disease. 18,19 The amount of plasma cfDNA increases in patients with solid tumours due to increased cell turnover. The DNA of cancer cells contributes to the concentration of cfDNA in the plasma and is called ctDNA.…”

Section: Circulating Cell-free Dnamentioning

confidence: 99%

Liquid Biopsy – Possibilities for Monitoring the Therapeutic Response in Non-Small Cell Lung Cancer

Raycheva¹,

Ivanov²,

Грудева-Попова³

2021

View full text Add to dashboard Cite

Lung cancer is the leading cause of death from malignancy worldwide. Its heterogeneity and tumour biology make treatment considerably more difficult. The introduction of target molecules heralded the beginning of the personalized medicine which tailors medical treatments to the molecular and genetic profile of a patient. Liquid biopsy is an innovative, non-invasive method which is used both for diagnostic purposes and for therapeutic monitoring. Liquid biopsy has the potential to help manage non-small cell lung cancer throughout all stages of this cancer: screening, detection of minimal residual disease to guide adjuvant treatment, early detection of relapse, systemic treatment initiation, monitoring of response to targeted or immune therapy, and the emergence of resistance to applied treatment. At present, the study of circulating tumour DNA is used in clinical practice, but circulating tumour cells, miRNAs, exosomes, and platelets formed in the tumour also show promising results.

show abstract

Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer

Cited by 22 publications

References 65 publications

Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?

Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?

The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management

Liquid Biopsy – Possibilities for Monitoring the Therapeutic Response in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About

Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer

Cited by 22 publications

References 65 publications

Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?

Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?

The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management

Liquid Biopsy &ndash; Possibilities for Monitoring&nbsp;the Therapeutic Response in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About

Liquid Biopsy – Possibilities for Monitoring the Therapeutic Response in Non-Small Cell Lung Cancer